Form 4: Annexon Director William Carson Receives Grant of 55,000 Stock Options

Annexon, Inc. Director William H. Carson was granted 55,000 stock options with an exercise price of $2.55, vesting on the earlier of June 5, 2026, or the next Annual Meeting.

Summary

• William H. Carson, a Director of Annexon, Inc. (ANNX), was granted 55,000 stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these stock options is $2.55 per share.
• The options will vest and become exercisable as to 100% of the total number of shares on the earlier of (i) the first anniversary of June 5, 2025, or (ii) the next Annual Meeting following June 5, 2025.
• Vesting is contingent upon Mr. Carson's continuous service as a director until the vesting date.
• The stock options have an expiration date of June 5, 2035.
• Following this transaction, William H. Carson beneficially owns 55,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine equity compensation grant to a director, which is a neutral to slightly positive event as it aligns interests, but does not indicate significant operational or financial news for the company.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The options provide a potential future upside for the director, contingent on the company's stock price appreciation above the exercise price.

Negatives

• The value of the options is entirely dependent on the future performance of Annexon's stock price.
• There is no immediate cash benefit to the director from this grant; value is realized only upon exercise and sale of shares.

Risks

• The value of the stock options could be negatively impacted if Annexon's stock price does not appreciate above the $2.55 exercise price.
• The options are subject to forfeiture if the reporting person's continuous service as a director terminates before the vesting date.

Future Outlook

The stock options are set to vest on the earlier of June 5, 2026, or the next Annual Meeting following June 5, 2025, provided the director maintains continuous service.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Annexon, Inc., as a form of long-term incentive compensation to align leadership interests with shareholder value.

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, which is a standard form of compensation for board service.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned interests between the director and company performance.
• Director: Receives a long-term incentive that ties personal wealth to the company's stock performance.

Next Steps

• The stock options will vest on the earlier of June 5, 2026, or the next Annual Meeting following June 5, 2025.
• Upon vesting, the director will have the right to exercise the options and acquire common stock.

Key Dates

Keywords

Annexon, ANNX, Form 4, stock option, insider transaction, director compensation, equity grant, beneficial ownership, vesting